secwatch.observer — SEC 8-K summary
======================================

Issuer:     Matinas BioPharma Holdings, Inc. (MTNB)
CIK:        0001582554
Form:       8-K
Filed at:   2023-03-15T23:59:59+00:00
Accession:  0001493152-23-007732
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Matinas BioPharma reports 2022 net loss $21M, cash $28.8M; LNC platform updates
-------------------------------------------------------------------------------

- Revenue $3.2M from BioNTech collaboration, vs $33K in 2021.
- Net loss $21.0M ($0.10/share) vs $23.7M ($0.11/share) in 2021.
- Cash and marketable securities $28.8M at Dec 31, 2022, sufficient into Q2 2024.
- Anticipates Q2 2023 in vivo data from BioNTech and National Resilience collaborations.
- Planned FDA meeting for MAT2203 Phase 3; potential BARDA/NIH funding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582554/000149315223007732/0001493152-23-007732-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582554/000149315223007732/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-007732

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer